雷帕霉素联合顺铂对CCL19调节头颈鳞状细胞癌细胞活性的影响

Objective To investigate the synergistic effects of rapamycin and cisplatin on head and neck squamous cancer cells regulated by chemokine( C-C motif) ligand 19 (CCL19). Methods The role of rapamycin and cisplatin was detected on cell-cycle and apoptosis in CCL19 induced PCI-4B and PCI-37B cells by methyl thiazolyl tetrazolium (MTT) and flow cytometry(FCM). Dose-effect relationship parameters and combination index(CI) were calculated on the median-effect equation and multiple drug effect equation using computer software CalcuSyn. Statistical analysis was performed by the unpaired student's t-test.Results Rapamycin and cisplatin could respectively increase the growth arrest, the proportion of G1 phase and apoptosis of CCL19 induced cancer cells (P ＜0. 05 ). Under inhibitory concentration 50% (IC50), CI was less than 1, and in IC75, it was more than 1 in PCI-4B cells. In PCI-37B cells, under IC75, CI was less than 1, and in IC90, it was more than 1. Conclusions Rapamycin and cisplatin can inhibit CCL19-regulated PCI-4B and PCI-37B cells' survival. The two drugs have synergistic effects when used in combination.

Effect of rapamycin combined with cisplatin on head and neck squamous cancer cells regulated by CCL19